Literature DB >> 17027743

Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.

Ralf Ziemek1, Albert Brennauer, Erich Schneider, Chiara Cabrele, Annette G Beck-Sickinger, Günther Bernhardt, Armin Buschauer.   

Abstract

With respect to the discovery and characterization of neuropeptide Y(2) receptor ligands as pharmacological tools or potential drugs, fluorescence- and luminescence-based assays were developed to determine both the affinity and the activity of receptor agonists and antagonists. A flow cytometric binding assay is described for the hY(2) receptor stably expressed in CHO cells using cy5-labeled porcine neuropeptide Y and compared with a radioligand binding assay. Binding of the fluorescent ligand was visualized by confocal microscopy. Stable co-transfection with the chimeric G protein Gq(i5) enabled the establishment of a spectrofluorimetric fura-2 and a flow cytometric fluo-4 calcium assay. Further stable expression of apoaequorin targeted to the mitochondria allowed the establishment of an aequorin assay which could be performed in the 96-well format. The shape of the concentration-response curves of porcine neuropeptide Y in the presence of the Y(2)-selective receptor antagonist BIIE0246, characteristic of either competitive or insurmountable antagonism, depended on the period of incubation with the cells. Functional data of Y(2) receptor agonists and antagonists determined in the fluorescence- and luminescence-based assays were in good agreement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027743     DOI: 10.1016/j.ejphar.2006.08.075

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

2.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

Review 3.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

4.  Differently fluorescence-labelled dibenzodiazepinone-type muscarinic acetylcholine receptor ligands with high M2R affinity.

Authors:  Corinna G Gruber; Andrea Pegoli; Christoph Müller; Lukas Grätz; Xueke She; Max Keller
Journal:  RSC Med Chem       Date:  2020-06-08

5.  Aequorin mutants with increased thermostability.

Authors:  Xiaoge Qu; Laura Rowe; Emre Dikici; Mark Ensor; Sylvia Daunert
Journal:  Anal Bioanal Chem       Date:  2014-08-02       Impact factor: 4.142

6.  The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.

Authors:  Martin Memminger; Max Keller; Miroslaw Lopuch; Nathalie Pop; Günther Bernhardt; Erwin von Angerer; Armin Buschauer
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

7.  Functional selectivity of GPCR-directed drug action through location bias.

Authors:  Roshanak Irannejad; Veronica Pessino; Delphine Mika; Bo Huang; Philip B Wedegaertner; Marco Conti; Mark von Zastrow
Journal:  Nat Chem Biol       Date:  2017-05-29       Impact factor: 15.040

8.  In Search of NPY Y4R Antagonists: Incorporation of Carbamoylated Arginine, Aza-Amino Acids, or d-Amino Acids into Oligopeptides Derived from the C-Termini of the Endogenous Agonists.

Authors:  Kilian K Kuhn; Timo Littmann; Stefanie Dukorn; Miho Tanaka; Max Keller; Takeaki Ozawa; Günther Bernhardt; Armin Buschauer
Journal:  ACS Omega       Date:  2017-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.